China Pharma Holding's EPS (Basic) for the
three
months ended in Mar. 2026 was €-0.04.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.39.
During the past 3 years, the average EPS without NRIGrowth Rate was 73.30% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 55.80% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 32.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, China Pharma Holding's highest 3-Year average EPS without NRI Growth Rate was 73.30% per year. The lowest was -33.90% per year. And the median was 19.75% per year.
China Pharma Holding (STU:XQJ) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
China Pharma Holding EPS (Diluted) Related Terms
China Pharma Holding EPS (Diluted) Historical Data
* Premium members only.
The historical data trend for China Pharma Holding's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:XQJ vs TXMD, RMTI, AYTU: EPS (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Pharma Holding PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's PE Ratio distribution charts can be found below:
* The bar in red indicates where China Pharma Holding's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
China Pharma Holding's Diluted EPS for the fiscal year that ended in Dec. 2025 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.39
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Pharma Holding (STU:XQJ) has a EPS (Diluted) of €-0.39 as of Mar. 2026. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on China Pharma Holding and its competitors.
Is China Pharma Holding's EPS (Diluted) too high?
China Pharma Holding's current EPS (Diluted) is €-0.39. Overall, China Pharma Holding has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does China Pharma Holding's EPS (Diluted) compare to TXMD and RMTI?
China Pharma Holding's EPS (Diluted) of €-0.39 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Drug Manufacturers company?
A good EPS (Diluted) depends on the Drug Manufacturers industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on China Pharma Holding and its competitors. China Pharma Holding's current EPS (Diluted) is €-0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Pharma Holding stock overvalued right now?
China Pharma Holding (STU:XQJ) has a current EPS (Diluted) of €-0.39. The stock's GF Value™ is €10.05, compared to a current price of €26.80 — trading 166.7% above its estimated fair value. The current EPS (Diluted) is €-0.39. China Pharma Holding's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For China Pharma Holding (STU:XQJ), the current EPS (Diluted) is €-0.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Pharma Holding (STU:XQJ) Overvalued in 2026?
Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued.
The current stock price of €26.80 is trading 166.7% above its estimated GF Value™ of €10.05.
Key valuation signals for STU:XQJ:
EPS (Diluted): €-0.39
GF Value™: €10.05 vs. price of €26.80 (166.7% above fair value)
No single metric tells the full story. See the STU:XQJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
26GF Score
Get the complete analysis for STU:XQJ
EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:XQJ has been successfully added to your 
